BOSTON & GENEVA--(BUSINESS WIRE)--PHT Corporation accomplished its 4th consecutive year of profitable growth in 2012 as sponsors, CROs and sites worldwide adopted its ePRO and eCOA Systems to collect patient-driven eData for clinical research programs.
2012 revenues increased by more than 25%, bolstering PHT’s 40% market share. PHT added 9 new clients through direct sales and increased sales through CRO partnerships which accounted for 20% of bookings. PHT expanded global headcount 25%, primarily in the Client Services, Customer Support, Engineering and Consulting Services areas.
PRO and eCOA Systems – PHT achieved a 100% increase in the adoption of NetPRO™, its Web-based system for collecting patient and clinician data. Strong demand continued for the SitePad® System which captures PROs and clinical data at the investigation site. PHT has implemented 600+ eCOA systems for 145 trial sponsors around the globe.
Therapeutic Areas – Sponsors and CROs are leveraging PHT ePRO and eCOA Systems for a broader range of indications and therapeutic areas including Rheumatoid Arthritis, Hemophilia, Diabetes and Psoriasis, in addition to Oncology and many Central Nervous System indications including Schizophrenia and Alzheimer’s.
PHT President and CEO Philip Lee said, “PHT experienced strong growth in 2012 because regulators and pharmaceutical executives recognize the scientific and business benefits of leveraging patient-driven eData in clinical research. Every employee at PHT shares a passion for helping scientists do better research.”
Global Recognition
Technology – PHT awarded a U.S. patent for LogPad® “Time Travel” technology for improved testing and patient eDiary training. Watch a short video on the technology: http://www.goo.gl/weCam
Events – Unanimous industry approval of the 16th Annual PRO & ePRO Congress – Clinical research professionals in the pharmaceutical and life science industries joined regulators, sponsors, sites and CROs to become experts in eCOA/ePRO implementation. Register for the 2013 PRO & eCOA Congresses, Baltimore, March 26-28 at http://www.goo.gl/Hfyc1 and Annecy, France May 28 – 30 at http://goo.gl/5s7Gd
Thought Leadership – PHT executives chaired panel discussions and presented at the annual DIA U.S. and European meetings. Watch brief videos of PHT co-founder Dr. Stephen Raymond http://goo.gl/Z9sBX and Europe General Manager, Valdo Arnera, MD http://www.goo.gl/qooQe on trends in clinical research.
Awards – Phil Lee, PHT President and CEO, was a finalist for the Ernst & Young New England Entrepreneur of the Year Award. Watch this brief video highlighting Phil’s achievements at PHT: http://goo.gl/UyTxK. He also was named an Innovation All Star by Mass High Tech and the Boston Business Journal.
Sheila Rocchio, PHT Vice President of Marketing and Product Management, won the Massachusetts Technology Leadership Council’s Emerging Executive of the Year award. Sheila also was named to the PharmaVOICE 100 list of the most influential executives in the life sciences industries, and was a finalist for the Partnerships in Clinical Trials Clinical Businesswoman of the Year award program. Watch a short video of Sheila’s vision for clinical research in 2013: http://goo.gl/PC7On.
About PHT Corporation
PHT Corporation helps pharmaceutical companies and CROs conduct clinical trial programs with greater confidence, ease and accuracy. Proven PHT eCOA Systems collect patient-driven eData via smartphones, tablets and the web. This data, available via the PHT StudyWorks® online portal, provides sponsors and clinicians with a real time window into how patients feel and function. The service and technology that PHT provides helps clients speed new therapies to market that ultimately improve patient quality of life around the world. PHT has helped trial sponsors collect patient-driven eData in 600+ global trials resulting in 16 regulatory approvals. PHT offers the regulatory, technological, and scientific expertise today’s market demands and patients deserve. Visit www.phtcorp.com for more information on PHT. Follow PHT on LinkedIn, Twitter and YouTube.